Progress in the clinical development of CX-2051, targeted at advanced colorectal cancer, with initial Phase 1a clinical data expected in the first half of 2025. CytomX maintains a strong financial ...

CytomX Therapeutics has updated its pipeline priorities for 2025, highlighting its lead program, CX-2051, a first-in-class PROBODY ADC targeting EpCAM for advanced metastatic colorectal cancer, with ...

Ford is turning to its softer side to improve the customer experience, or CX. Ford this spring is rolling out an airline-style rewards points program and is training call center reps to be friendlier ...

The Daniel Group, a leader in B2B customer experience, introduces the CX Institute, offering training and coaching to enhance CX programs. Leveraging insights from one million surveys, the initiative ...